Xenon
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3650 Gilmore Way Suite 200, Burnaby, Bri...Phone Number
(604) 484-3300Website
www.xenon-pharma.comRevenue
-Stock Symbol
XENEIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Xenon
Xenon is a clinical stage biopharmaceutical company founded in 1996 and headquartered in Canada. The company focuses on developing innovative therapeutics for patients with neurological disorders, particularly rare central nervous system conditions. Xenon specializes in creating novel neurology therapies that address areas of high unmet medical need, with a primary focus on treatments for epilepsy. The company maintains a product pipeline aimed at improving quality of life for patients with various neurological conditions through pharmaceutical innovation.Explore more
Xenon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xenon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Xenon has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Xenon has new funding data
Click to see if Xenon had a recent Job posting/layoffs
Check out if Xenon is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Xenon
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Xenon recently announced quarterly report
Website visits: Recent activity has been detected on your website
Xenon, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Xenon launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Xenon
Compare insights from companies similar to Xenon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Xenon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xenon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xenon.
Xenon financials insights
Gather financial insights about Xenon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Corporate Investment
$5.3M
2014
Stock Offering
$38.2M
2016
Stock Offering
$25.9M
2018
Stock Offering
$50M
Stock Offering
$63M
2019
Corporate Investment
$50M
2020
Stock Offering
$69M
Xenon Tech Stack
A closer look at the technologies used by Xenon
Most Recent Scoops
Open Position
Open Position
Hiring Plans
Xenon has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Project
Clinical Operations
Xenon News & Media
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsColleen Alabiso - Senior Vice President of Corporate...Xenon Reports Q2 2026 Financial Results and Provides Business Update
VANCOUVER, BC and BOSTON, MA, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eleven new non-officer employees consisting of an aggregate of 32,758 share options and 19,013 restricted share units (RSUs). All of the foregoing share options and RSUs were
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Xenon
Sign Up For FreeTo access detailed company insights
Xenon is a clinical stage biopharmaceutical company founded in 1996 and headquartered in Canada. The company focuses on developing innovative therapeutics for patients with neurological disorders, particularly rare central nervous system conditions. Xenon specializes in creating novel neurology therapies that address areas of high unmet medical nee... Read More
